We have shown that CD36 is downregulated in primary FBs when cocultured with tumor epithelial cells or incubated with the recombinant protein activin A in a dose-dependent manner (2.25 ng/mL to 20 ng/mL) [10] with the proper controls (e.g., activin A neutralizing antibody). The gene discussed is CD36; the disease is neoplasm.